Ranbaxy to pay $500mn to US Department of Justice for settlement of charges related to drug safety

By Religare
Subscribe to GoodReturns
For Quick Alerts
Subscribe Now  
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts
    Ranbaxy to pay $500mn to US Department of Justice
    In a largest ever settlement involving a generic drug maker over drug safety, Ranbaxy Laboratories Ltd, majority-owned by Japan's Daiichi Sankyo Co Ltd., pleaded guilty to felony charges and will pay USD 500 million in civil and criminal fines under the settlement agreement with the US Department of Justice.
     

    The fine includes USD 150 million in payments for a criminal fine and forfeiture and USD 350 million in payments for civil claims.

    Ranbaxy USA was under investigation by the government into its manufacturing practices and for falsifying data.

    The company pleaded guilty to three felony counts related to the manufacturing of drugs at two Indian locations that did not meet safety standards and to four counts of making material false statements.

    Read more about: ranbaxy laboratories
    Company Search
    Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

    Find IFSC

    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more